Stock 688222 HITGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News HitGen Inc.

Equities

688222

CNE1000040G3

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
13.08 CNY +0.31% Intraday chart for HitGen Inc. -2.24% -12.74%
04-24 HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-23 HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Chengdu HitGen and the Structural Genomics Consortium have reached A Cooperation in the research and development of new drugs based on DEL technology Release time, 2023-09-28
AQ
HitGen Receives 10 Million Yuan in Government Subsidies
MT
The Structural Genomics Consortium and HitGen Inc. Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CI
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
AQ
HitGen Inc.(XSSC:688222) added to S&P Global BMI Index
CI
HitGen Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chengdu Hittech and Nested Therapeutics signed a new drug research and development service contract based on DEL technology
AQ
HitGen Inc. Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics, Inc
CI
HitGen Inc. Launches A Newly Upgraded Version of OpenDELâ„¢, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research
CI
HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Certain A Shares of HitGen Inc. are subject to a Lock-Up Agreement Ending on 16-APR-2023.
CI
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.
CI
HitGen Inc.'s Equity Buyback announced on July 1, 2022, has expired with 1,238,700 shares, representing 0.34% for CNY 20 million.
CI
HitGen Inc. Announces Research Agreement with Nitrase Therapeutics, Inc. Focused on DNA-Encoded Library Based Drug Discovery
CI
DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CI
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688222 Stock
  4. News HitGen Inc.